Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, V. O. Speights, Nicholas J. Vogelzang, Donald L. Trump, Ralph W deVere White, Michael F. Sarosdy, David P. Wood, Derek Raghavan, E. David Crawford

Research output: Contribution to journalArticle

1466 Citations (Scopus)

Abstract

BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy. METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001). CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.

Original languageEnglish (US)
Pages (from-to)859-866
Number of pages8
JournalNew England Journal of Medicine
Volume349
Issue number9
DOIs
StatePublished - Aug 28 2003

Fingerprint

Cystectomy
Urinary Bladder Neoplasms
Drug Therapy
Vinblastine
Residual Neoplasm
Methotrexate
Doxorubicin
Cisplatin
Survival
Muscles
Intention to Treat Analysis
Aptitude
Group Psychotherapy
Therapeutics
Neoplasm Metastasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., ... Crawford, E. D. (2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New England Journal of Medicine, 349(9), 859-866. https://doi.org/10.1056/NEJMoa022148

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. / Grossman, H. Barton; Natale, Ronald B.; Tangen, Catherine M.; Speights, V. O.; Vogelzang, Nicholas J.; Trump, Donald L.; deVere White, Ralph W; Sarosdy, Michael F.; Wood, David P.; Raghavan, Derek; Crawford, E. David.

In: New England Journal of Medicine, Vol. 349, No. 9, 28.08.2003, p. 859-866.

Research output: Contribution to journalArticle

Grossman, HB, Natale, RB, Tangen, CM, Speights, VO, Vogelzang, NJ, Trump, DL, deVere White, RW, Sarosdy, MF, Wood, DP, Raghavan, D & Crawford, ED 2003, 'Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer', New England Journal of Medicine, vol. 349, no. 9, pp. 859-866. https://doi.org/10.1056/NEJMoa022148
Grossman, H. Barton ; Natale, Ronald B. ; Tangen, Catherine M. ; Speights, V. O. ; Vogelzang, Nicholas J. ; Trump, Donald L. ; deVere White, Ralph W ; Sarosdy, Michael F. ; Wood, David P. ; Raghavan, Derek ; Crawford, E. David. / Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. In: New England Journal of Medicine. 2003 ; Vol. 349, No. 9. pp. 859-866.
@article{687ab503f3904613930e402f0c93fc60,
title = "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer",
abstract = "BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy. METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001). CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.",
author = "Grossman, {H. Barton} and Natale, {Ronald B.} and Tangen, {Catherine M.} and Speights, {V. O.} and Vogelzang, {Nicholas J.} and Trump, {Donald L.} and {deVere White}, {Ralph W} and Sarosdy, {Michael F.} and Wood, {David P.} and Derek Raghavan and Crawford, {E. David}",
year = "2003",
month = "8",
day = "28",
doi = "10.1056/NEJMoa022148",
language = "English (US)",
volume = "349",
pages = "859--866",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "9",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

AU - Grossman, H. Barton

AU - Natale, Ronald B.

AU - Tangen, Catherine M.

AU - Speights, V. O.

AU - Vogelzang, Nicholas J.

AU - Trump, Donald L.

AU - deVere White, Ralph W

AU - Sarosdy, Michael F.

AU - Wood, David P.

AU - Raghavan, Derek

AU - Crawford, E. David

PY - 2003/8/28

Y1 - 2003/8/28

N2 - BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy. METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001). CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.

AB - BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy. METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001). CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0041429507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041429507&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa022148

DO - 10.1056/NEJMoa022148

M3 - Article

VL - 349

SP - 859

EP - 866

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -